Bridge Biotec (Bridge) is a start-up Biotechnology Company that is developing novel, safe and effective treatments for serious inflammatory diseases, such as inflammatory bowel disease.
Bridge is an ambitious company aiming to be revenue generating within 18 months by taking the lead project to exit, via out-licencing or trade sale, by investing in the innovative programs to treat serious inflammatory disorders.
We have licenced two very important components that we plan to combine to form a range of therapies aimed at treating serious inflammatory diseases.
- Highly potent and highly specific novel peptide (“small protein”) anti-inflammatory therapeutics
- Safe, nanoparticle delivery polmer, that will take the peptides into human cells and switch off inflammation
By combining these two important components to form its lead compound JEL3108, a new medicine to safely treat the life threatening and disabling inflammatory disease called inflammatory bowel disease (IBD).
Bridge is currently seeking a total of £700,000 seed funding to initiate the company, employ key personnel, secure access to laboratory space and develop the lead formulation to provide key ex-vivo proof of concept studies in human tissue. It will also provide a short run-way to raise a further £5 million required for full pre-clinical development including safety pharmacology, GMP CMC formulation and toxicology.
During this time the funding will facilitate the set-up of an international Adaptive Development Committee, led by Bridge, that will work closely with international and regional regulatory authorities to design and gain approval for a full adaptive clinical development plan. These data will support a further raise of £20-30 million to progress the lead compound into clinical proof of concept studies in inflammatory bowel disease, and progress the backup programs, within 5 years of initial funding.